



Open Access Journal by MDPI

Tracked for Impact Factor

Immuno

A red-tinted microscopic image showing several cells, with a large central cell containing two smaller, bright, spherical structures.

[mdpi.com/
journal/
immuno](https://mdpi.com/journal/immuno)



Message from the Editor-in-Chief

Immuno provides an advanced forum for studies on all aspects of immunological science and medicine. Our fields of interest include basic and clinical research on the developing fields of immunology, such as immunogenomics, immunoproteomics, immunometabolomics, and immunomicrobiomics, which should contribute to improving the understanding of the yet-unknown aspects of the human immune system, as well as the development of innovative immunotherapy and vaccines through translational research. In addition, we are planning a series of Special Issues focusing on immunology topics of particular interest and importance. We hope that the advantages of open access, high-quality standards, and rapid publication will encourage scientists and practitioners to choose *Immuno* to disseminate their research and opinion. We are looking forward to receiving your submissions to *Immuno*.

Editor-in-Chief

Prof. Dr. Toshihiko Torigoe

Aims

Immuno [ISSN 2673-5601] provides an advanced forum for studies related to basic and clinical immunology research. It publishes reviews, regular research papers, conference reports and communications as well as Special Issues on particular subjects.

The aim of *Immuno* is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, the journal has no restrictions regarding the maximum length of papers. Full experimental details should be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the immunology community. *Immuno* requires authors to publish all experimental controls and make full datasets available where possible (see the guidelines on Supplementary Materials and references to unpublished data).

Scope

- Innate immunity
- Acquired immunity
- Synthetic immunity
- Structural immunology
- Immunogenetics, immunogenomics, immunoproteomics, immunometabolomics
- Infectious immunology and vaccines
- Cancer immunology
- Immunotherapy
- Autoimmunity and immunoregulation
- Developmental immunology
- Immunodeficiency
- Reproductive immunology
- Transplantation immunology
- Immunodermatology
- Mucosal immunology
- Neuroimmunology
- Immunopathology and immunohistology
- Clinical/Translational immunology

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

Rapid Publication

A first decision is provided to authors approximately 20.7 days after submission; acceptance to publication is undertaken in 4.4 days (median values for papers published in this journal in the second half of 2023)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

immuno@mdpi.com

MDPI

St. Alban-Anlage 66

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

